Table 2.
Characteristics of DRs and RECIST v1.1 defined PD without new lesions before and after PSM
| Characteristics n (%) | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
| RECIST v1.1 defined PD without new lesions N = 84 | DRs N = 52 | p value | RECIST v1.1 defined PD without new lesions N = 40 | DRs N = 40 | p value | |
| Age [mean (SD)] | 57.80 (10.11) | 56.98 (11.10) | 0.660 | 57.38 (10.93) | 57.80 (10.77) | 0.816 |
| Sex | ||||||
| Male | 61 (72.6) | 41 (78.8) | 0.415 | 31 (77.5) | 31 (77.5) | 1.000 |
| Female | 23 (27.4) | 11 (21.2) | 9 (22.5) | 9 (22.5) | ||
| Histology | ||||||
| Adenocarcinoma | 38 (45.2) | 31 (59.6) | 0.257 | 20 (50.0) | 23 (57.5) | 0.598 |
| Squamous-cell carcinoma | 36 (42.9) | 17 (32.7) | 13 (32.5) | 13 (32.5) | ||
| Other | 10 (11.9) | 4 (7.7) | 7 (17.5) | 4 (10.0) | ||
| Treatment | ||||||
| PD-1 | 81 (96.4) | 50 (96.2) | 1.000 | 38 (95.0) | 38 (95.0) | 1.000 |
| PD-L1 | 3 (3.6) | 2 (3.8) | 2 (5.00) | 2 (5.00) | ||
| Combined chemotherapy | ||||||
| Yes | 21 (25.0) | 19 (36.5) | 0.151 | 13 (32.5) | 17 (42.5) | 0.356 |
| No | 63 (75.0) | 33 (63.5) | 27 (67.5) | 23 (57.5) | ||
| Number of prior therapy | ||||||
| 0 | 7 (8.3) | 19 (36.5) | 0.000 | 7 (17.5) | 7 (17.5) | 1.000 |
| ≥ 1 | 77 (91.7) | 33 (63.5) | 33 (82.5) | 33 (82.5) | ||
| PD-L1 expression [mean (SD)] | 26.86 (24.98) | 32.12 (25.39) | 0.238 | 32.93 (27.48) | 32.55 (26.06) | 0.950 |
| Stage | ||||||
| III | 8 (9.5) | 6 (11.5) | 0.707 | 5 (12.5) | 5 (12.5) | 1.000 |
| IV | 76 (90.5) | 46 (88.5) | 35 (87.5) | 35 (87.5) | ||
| Combined ICIs | ||||||
| Yes | 2 (2.4) | 1 (1.9) | 1.000 | 2 (5.0) | 1 (2.5) | 1.000 |
| No | 82 (97.6) | 51 (98.1) | 38 (95.0) | 39 (97.5) | ||
| Dosage of ICIs | ||||||
| Standard | 77 (91.7) | 52 (100) | 0.044 | 40 (100) | 40 (100) | – |
| Nonstandard | 7 (8.3) | 0 (0.00) | 0 (0.00) | 0 (0.00) | ||